# Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

> **NCT06658951** · NA · RECRUITING · sponsor: **UTC Therapeutics Inc.** · enrollment: 30 (estimated)

## Conditions studied

- HER2-positive Advanced Malignant Solid Tumors

## Interventions

- **BIOLOGICAL:** Anti-HER2 CAR-T cells

## Key facts

- **NCT ID:** NCT06658951
- **Lead sponsor:** UTC Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-03
- **Primary completion:** 2027-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06658951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06658951, "Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06658951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*